首页> 外文期刊>Translational psychiatry. >Structural neuroimaging biomarkers for obsessive-compulsive disorder in the ENIGMA-OCD consortium: medication matters
【24h】

Structural neuroimaging biomarkers for obsessive-compulsive disorder in the ENIGMA-OCD consortium: medication matters

机译:雌性神经影像生物标志物在ENIGMA-OCD联盟中的强迫症:药物问题

获取原文
           

摘要

No diagnostic biomarkers are available for obsessive-compulsive disorder (OCD). Here, we aimed to identify magnetic resonance imaging (MRI) biomarkers for OCD, using 46 data sets with 2304 OCD patients and 2068 healthy controls from the ENIGMA consortium. We performed machine learning analysis of regional measures of cortical thickness, surface area and subcortical volume and tested classification performance using cross-validation. Classification performance for OCD vs. controls using the complete sample with different classifiers and cross-validation strategies was poor. When models were validated on data from other sites, model performance did not exceed chance-level. In contrast, fair classification performance was achieved when patients were grouped according to their medication status. These results indicate that medication use is associated with substantial differences in brain anatomy that are widely distributed, and indicate that clinical heterogeneity contributes to the poor performance of structural MRI as a disease marker.
机译:没有诊断生物标志物可用于强迫症(OCD)。在这里,我们旨在识别OCD的磁共振成像(MRI)生物标志物,使用具有2304名OCD患者的46个数据集和2068个来自ENIGMA联盟的2068名健康对照。我们使用交叉验证对了皮质厚度,表面积和皮质波动体积的区域测量进行了机器学习分析,并使用交叉验证进行了分类性能。使用具有不同分类器的完整样本和交叉验证策略的完整样本的OCD与控制的分类性能很差。当模型在来自其他网站的数据上验证时,模型性能没有超过机会级别。相比之下,当患者根据其药物状态进行分组时,实现了公平的分类性能。这些结果表明,药物用途与广泛分布的脑解剖学的显着差异有关,并且表明临床异质性有助于结构MRI作为疾病标记的差的性能。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号